Roanna Ruiz
Stock Analyst at Leerink Partners
(0.86)
# 3,926
Out of 5,182 analysts
60
Total ratings
35%
Success rate
-15.3%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Outperform | $83 → $84 | $66.25 | +26.79% | 2 | Feb 26, 2026 | |
| IBIO iBio, Inc. | Initiates: Outperform | $2 | $1.92 | +4.17% | 1 | Oct 17, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $6.04 | +49.01% | 7 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $1.42 | +392.96% | 1 | Apr 28, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $7.49 | +140.32% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.82 | -45.05% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $10.67 | +87.44% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $8.40 | +221.43% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $4.15 | +213.25% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $6.02 | +132.56% | 1 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $330 | $574.29 | -42.54% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $46.57 | -46.32% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $13.79 | +255.33% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $5.61 | +6.95% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $31.94 | -40.51% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $82.88 | +44.79% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $6.51 | +668.05% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $14.50 | +175.86% | 6 | Oct 19, 2022 |
Cytokinetics
Feb 26, 2026
Maintains: Outperform
Price Target: $83 → $84
Current: $66.25
Upside: +26.79%
iBio, Inc.
Oct 17, 2025
Initiates: Outperform
Price Target: $2
Current: $1.92
Upside: +4.17%
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $6.04
Upside: +49.01%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $1.42
Upside: +392.96%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $7.49
Upside: +140.32%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.82
Upside: -45.05%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $10.67
Upside: +87.44%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $8.40
Upside: +221.43%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $4.15
Upside: +213.25%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $6.02
Upside: +132.56%
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $574.29
Upside: -42.54%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $46.57
Upside: -46.32%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $13.79
Upside: +255.33%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $5.61
Upside: +6.95%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $31.94
Upside: -40.51%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $82.88
Upside: +44.79%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $6.51
Upside: +668.05%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $14.50
Upside: +175.86%